Table 2.
Clinicopathological features between Groups L–H and L–L
| Group L–H, n = 30 | Group L–L, n = 39 | p value | |
|---|---|---|---|
| Age (median, years)† | 66.5 (48–76) | 67 (40–82) | 0.216 |
| Gender (%) | 0.159 | ||
| Male | 26 (86.7%) | 38 (97.4%) | |
| Female | 4 (13.3%) | 1 (2.6%) | |
| Location of tumor (%) | 0.593 | ||
| Ut | 2 (6.7%) | 5 (12.8%) | |
| Mt | 17 (56.7%) | 23 (59.0%) | |
| Lt and Ae | 11 (36.7%) | 11 (28.2%) | |
| Clinical stage, TNM 8th (%) | 0.132 | ||
| Stage I | 10 (33.3%) | 5 (12.8%) | |
| Stage II | 8 (26.7%) | 17 (43.6%) | |
| Stage III | 11 (36.7%) | 13 (33.3%) | |
| Stage IVA | 1 (3.3%) | 4 (10.3%) | |
| Preoperative therapy (%) | 1.000 | ||
| None | 11 (36.7%) | 14 (35.9%) | |
| NAC | 19 (63.3%) | 25 (64.1%) | |
| Multidisciplinary team support (%) | 12 (40.0%) | 10 (25.6%) | 0.298 |
| Surgical approach (%) | 1.000 | ||
| Thoracotomy | 13 (43.3%) | 17 (43.6%) | |
| MIE | 17 (56.7%) | 22 (56.4%) | |
| LN dissection (%) | 0.128 | ||
| 2-field | 1 (3.3%) | 6 (15.4%) | |
| 3-field | 29 (96.7%) | 33 (84.6%) | |
| Reconstruct organ (%) | 0.690 | ||
| Gastric conduit | 26 (86.7%) | 36 (92.3%) | |
| Colon conduit | 4 (13.3%) | 3 (7.7%) | |
| Jejunostomy (%) | 16 (53.3%) | 20 (51.3%) | 1.000 |
| Operation time (median, min) † | 559.5 (318–982) | 645 (441–927) | 0.055 |
| Complications, C–D grade, ≥ 2 (%) | |||
| All infectious complications | 12 (40.0%) | 26 (66.7%) | 0.032 |
| AL | 2 (6.7%) | 12 (30.8%) | 0.016 |
| Pneumonia | 10 (33.3%) | 17 (43.6%) | 0.460 |
| SSI | 4 (13.3%) | 16 (41.0%) | 0.016 |
| Pathological stage, TNM 8th (%) | 0.320 | ||
| Stage 0 | 3 (10.0%) | 0 (0.0%) | |
| Stage IA/IB | 5 (16.7%) | 4 (10.3%) | |
| Stage IIA/IIB | 6 (20.0%) | 10 (25.6%) | |
| Stage IIIA/IIIB | 11 (36.7%) | 16 (37.9%) | |
| Stage IVA/IVB | 5 (16.7%) | 9 (23.1%) | |
| Adjuvant therapy (%) | 0.336 | ||
| None | 13 (43.3%) | 22 (56.4%) | |
| Chemotherapy | 17 (56.7%) | 17 (43.6%) | |
| POM1 serum albumin† | 3.8 (3.3–4.4) | 3.0 (1.6–3.7) | < 0.001 |
| POM1 serum total lymphocyte count† | 1218.5 (590–2357) | 972 (300–2244) | 0.011 |
| POM1 PNI† | 44.5 (40.9–51.3) | 35.1 (20.9–40.8) | < 0.001 |
| Recurrence site* (%) | |||
| Local | 2 (6.7%) | 5 (12.8%) | 0.690 |
| Regional LN | 6 (20.0%) | 16 (41.0%) | 0.074 |
| Distant organ | 8 (26.7%) | 16 (41.0%) | 0.308 |
| Death unrelated to esophageal cancer (%) | 1 (3.3%) | 1 (2.6%) | 1.000 |
Ut Upper thoracic esophagus, Mt middle thoracic esophagus, Lt lower thoracic esophagus; Ae Abdominal esophagus, NAC neoadjuvant chemotherapy, MIE minimal invasive esophagectomy, LN lymph node, C–D Clavien–Dindo, AL anastomotic leakage, SSI surgical site infection, POM postoperative month, PNI prognostic nutritional index
†Values are presented as median (range)
*Some patients were existed multiple sites of recurrence